Quick Answer
Transcode Therapeutics, Inc. reported Earnings Per Share Diluted of $47.14 (loss) per share for the year ending 2024.
- Transcode Therapeutics, Inc. showed an increase of +98.6% in Earnings Per Share Diluted from 2023 to 2024.
- This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2020 to 2024), Transcode Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 9,143.1%.
- Historical annual values: Fiscal year 2024: $47.14 (loss) per share | Fiscal year 2023: $3,419.01 (loss) per share | Fiscal year 2022: $1,082.79 (loss) per share | Fiscal year 2021: $0.81 (loss) per share | Fiscal year 2020: $0.51 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: